Truong Thanh Tung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Truong Thanh Tung has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Nguyen-Hai Nam
Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Vietnam
13 shared publications Jong Soon Kang
Korea Research Institute of Bioscience and Biotechnology, Cheongju, Chungbuk, Republic of Korea
11 shared publications- Huy Luong Xuan
Department of Chemical Engineering, School of Chemistry and Life Sciences, Hanoi University of Science and Technology, Hanoi, Vietnam
9 shared publications Do Thi Mai Dung
Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Viet Nam
7 shared publications- John Nielsen
Department of Basic Sciences and Environment, Faculty of Life Sciences, University of Copenhagen, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark
7 shared publications - Sang-Bae Han
College of Pharmacy, Chungbuk National University, 194-31, Osongsaengmyung-1, Heungdeok, Cheongju, Chungbuk 28160, Republic of Korea
7 shared publications
Latest Publications
- 24 September 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (9) , 3011-3034
Multifunctional biological roles of Fusaric acid and its derivatives in the Diverse Kingdoms of Life: Insights from More Than Nine Decades of Research
Fusaric acid (5-butylpicolinic) is a mycotoxin produced by Fusarium species as a biological response to external environmental factors. It exhibits hepatotoxicity in humans upon consumption of contaminated agricultural products. The compound was first reported nearly 92 years ago by Yabuta et al. Interestingly, Fusarium spp. can produce this compound in very large amounts, up to 1080 μg per gram of total biomass. However, the primary biological function of fusaric acid is still not fully understood. Numerous studies have attempted to clarify the biological functions of fusaric acid across various species, including virus, fungi, bacteria, mammals, and humans. Several preclinical studies and clinical trials have evaluated its therapeutic potential for human diseases. However, despite these efforts, fusaric acid has not progressed into an approved therapeutic agent, highlighting both its biological complexity and the challenges associated with its clinical development. To date, none of the works have comprehensively enumerated the multifunctional biological roles of fusaric acid and its derivatives. In this review, marking the 90th + anniversary of its discovery, we discuss the most notable roles of fusaric acid across diverse kingdoms of life. Graphical Abstract
- 24 September 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (9) , 3011-3034
Multifunctional biological roles of Fusaric acid and its derivatives in the Diverse Kingdoms of Life: Insights from More Than Nine Decades of Research
Fusaric acid (5-butylpicolinic) is a mycotoxin produced by Fusarium species as a biological response to external environmental factors. It exhibits hepatotoxicity in humans upon consumption of contaminated agricultural products. The compound was first reported nearly 92 years ago by Yabuta et al. Interestingly, Fusarium spp. can produce this compound in very large amounts, up to 1080 μg per gram of total biomass. However, the primary biological function of fusaric acid is still not fully understood. Numerous studies have attempted to clarify the biological functions of fusaric acid across various species, including virus, fungi, bacteria, mammals, and humans. Several preclinical studies and clinical trials have evaluated its therapeutic potential for human diseases. However, despite these efforts, fusaric acid has not progressed into an approved therapeutic agent, highlighting both its biological complexity and the challenges associated with its clinical development. To date, none of the works have comprehensively enumerated the multifunctional biological roles of fusaric acid and its derivatives. In this review, marking the 90th + anniversary of its discovery, we discuss the most notable roles of fusaric acid across diverse kingdoms of life. Graphical Abstract
- Open Access
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 40085-40104
2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity
Histone deacetylase (HDAC) inhibitors are important epigenetic anticancer agents that regulate gene expression, induce cell cycle arrest, and promote apoptosis.
- 12 August 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (37) , 40085-40104
Open Access2-Oxoindoline-based hydroxamic acids: novel HDAC inhibitors with promising anticancer activity
Histone deacetylase (HDAC) inhibitors are important epigenetic anticancer agents that regulate gene expression, induce cell cycle arrest, and promote apoptosis.
- 19 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130509
Novel 2-mercaptoquinazolinone N-hydroxycinnamamides as histone deacetylase inhibitors: design, synthesis, and anticancer evaluation
- 19 December 2025
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 132, 130509
Novel 2-mercaptoquinazolinone N-hydroxycinnamamides as histone deacetylase inhibitors: design, synthesis, and anticancer evaluation
- 11 November 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (11) , 2007-2027
Exploration of 2-Mercaptoquinazolin-4(3H)-one Based N-Hydroxyheptanamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Anticancer Bioevaluation
Objective Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics by regulating gene expression, halting cell cycle progression, and inducing apoptosis. This study explores the structure–activity relationship of 2-mercaptoquinazolin-4(3H)-one derivatives as potential anticancer agents and HDAC inhibitors. Methods The library compounds were prepared via a three-step pathway by incorporating 2-mercaptoquinazoline and a hydroxamic acid moiety. The cytotoxicity of 27 synthesized hydroxamic acid derivatives was evaluated against SW620 (colon cancer), MDA-MB-231 (breast cancer), and MRC-5 (normal lung fibroblast) cell lines. Molecular docking studies on HDAC-isoforms for the 4a–i were also performed to identify the essential structural features that contribute to the biological activities. Results The results demonstrated that substituents at the N-3 position significantly influenced anticancer activity, with methyl-substituted derivatives (4a-i) exhibiting the highest cytotoxicity, followed by phenyl-substituted (7a-i) and benzyl-substituted (10a-i) compounds. Among the tested compounds, 4a (-H) and 4c (7-CH₃) showed as the most potent active compounds, with IC50 values of 4.24 ± 1.16 µM and 3.61 ± 0.32 µM against SW620 cells, and 2.93 ± 0.68 µM and 3.34 ± 0.32 µM against MDA-MB-231 cells, respectively. HDAC inhibition assays revealed that 4a-d and 4 g exhibited superior inhibitory activity compared to SAHA. Further investigation of 4a and 4c in SW620 cells showed that both compounds induced G2/M phase cell cycle arrest and promoted apoptosis, supporting their potential as promising HDAC inhibitors with anticancer properties. Conclusions Among the most active compounds, 4a and 4c may serve as promising leads for the development of novel HDAC-targeted anticancer therapies.
- 11 November 2025
- Published by Springer Nature in Pharmaceutical Research
- Vol. 42 (11) , 2007-2027
Exploration of 2-Mercaptoquinazolin-4(3H)-one Based N-Hydroxyheptanamides as Histone Deacetylase Inhibitors: Design, Synthesis, and Anticancer Bioevaluation
Objective Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics by regulating gene expression, halting cell cycle progression, and inducing apoptosis. This study explores the structure–activity relationship of 2-mercaptoquinazolin-4(3H)-one derivatives as potential anticancer agents and HDAC inhibitors. Methods The library compounds were prepared via a three-step pathway by incorporating 2-mercaptoquinazoline and a hydroxamic acid moiety. The cytotoxicity of 27 synthesized hydroxamic acid derivatives was evaluated against SW620 (colon cancer), MDA-MB-231 (breast cancer), and MRC-5 (normal lung fibroblast) cell lines. Molecular docking studies on HDAC-isoforms for the 4a–i were also performed to identify the essential structural features that contribute to the biological activities. Results The results demonstrated that substituents at the N-3 position significantly influenced anticancer activity, with methyl-substituted derivatives (4a-i) exhibiting the highest cytotoxicity, followed by phenyl-substituted (7a-i) and benzyl-substituted (10a-i) compounds. Among the tested compounds, 4a (-H) and 4c (7-CH₃) showed as the most potent active compounds, with IC50 values of 4.24 ± 1.16 µM and 3.61 ± 0.32 µM against SW620 cells, and 2.93 ± 0.68 µM and 3.34 ± 0.32 µM against MDA-MB-231 cells, respectively. HDAC inhibition assays revealed that 4a-d and 4 g exhibited superior inhibitory activity compared to SAHA. Further investigation of 4a and 4c in SW620 cells showed that both compounds induced G2/M phase cell cycle arrest and promoted apoptosis, supporting their potential as promising HDAC inhibitors with anticancer properties. Conclusions Among the most active compounds, 4a and 4c may serve as promising leads for the development of novel HDAC-targeted anticancer therapies.
- 8 September 2025
- Published by Wiley in Peptide Science
- Vol. 117 (5)
Balancing Length and Hydrophobicity in Cationic Amphipathic Peptides: Insights From Biological Analysis and Molecular Simulation
Cationic amphipathic antimicrobial peptides (AMPs) have garnered attention for their dual antibacterial and anticancer activities. However, the structural determinants underlying their selective bioactivity remain incompletely defined. In this study, we investigate the structure–function relationships of four representative peptides: MPCK, LTX315, CnAMP1, and its C‐terminally amidated analog, CAP, through a combination of experimental assays and molecular dynamics (MD) simulations. CAP exhibited enhanced helicity relative to CnAMP1, yet neither peptide showed significant anticancer or antibacterial activity, suggesting that increased helicity alone is insufficient for potency. In contrast, LTX315 displayed strong activity, likely driven by its higher net charge and hydrophobicity. MPCK demonstrated the most potent anticancer effect, potentially due to its extended length and stable helical structure, but was less active against bacteria and more hemolytic than LTX315. Molecular dynamics simulations further demonstrated how structural parameters govern lipid selectivity and membrane perturbation. Our findings highlight that balancing peptide length and hydrophobicity provides a rational basis for developing potent anticancer and antimicrobial peptides with improved selectivity.
- 8 September 2025
- Published by Wiley in Peptide Science
- Vol. 117 (5)
Balancing Length and Hydrophobicity in Cationic Amphipathic Peptides: Insights From Biological Analysis and Molecular Simulation
Cationic amphipathic antimicrobial peptides (AMPs) have garnered attention for their dual antibacterial and anticancer activities. However, the structural determinants underlying their selective bioactivity remain incompletely defined. In this study, we investigate the structure–function relationships of four representative peptides: MPCK, LTX315, CnAMP1, and its C‐terminally amidated analog, CAP, through a combination of experimental assays and molecular dynamics (MD) simulations. CAP exhibited enhanced helicity relative to CnAMP1, yet neither peptide showed significant anticancer or antibacterial activity, suggesting that increased helicity alone is insufficient for potency. In contrast, LTX315 displayed strong activity, likely driven by its higher net charge and hydrophobicity. MPCK demonstrated the most potent anticancer effect, potentially due to its extended length and stable helical structure, but was less active against bacteria and more hemolytic than LTX315. Molecular dynamics simulations further demonstrated how structural parameters govern lipid selectivity and membrane perturbation. Our findings highlight that balancing peptide length and hydrophobicity provides a rational basis for developing potent anticancer and antimicrobial peptides with improved selectivity.
- Open Access
- 5 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331796
Indolicidin derivatives as potent dual-action antifungal and antibacterial agents for the treatment of skin infections: A comprehensive study from in vitro to in vivo evaluation
As listed by the WHO, the emergence of antibiotic-resistant pathogens, particularly Staphylococcus aureus and Pseudomonas aeruginosa, highlights the urgent need for novel antimicrobial agents. In parallel, fungal infections, especially those caused by Candida albicans, have also become increasingly prevalent and clinically challenging, further emphasizing the necessity for broad-spectrum therapeutic strategies. In particular, skin and soft tissue infections (SSTIs) caused by these bacteria and fungal are common in humans and can lead to severe complications if left untreated. Antimicrobial peptides (AMPs) have gained significant attention due to their broad-spectrum antimicrobial activity and immunomodulatory effects. Indolicidin, a naturally occurring cationic AMP, has demonstrated potent antibacterial and antifungal properties. In this study, we designed and synthesized a novel Indolicidin-derivative peptide IND-4,11K to enhance their antimicrobial activity and stability. The peptide was evaluated in vitro for their antimicrobial efficacy against Gram-positive, Gram-negative bacteria and Candida albicans. IND-4,11K was then prepared in 0–2% cream formula for in vivo testing in rabbit models. These findings suggest that modified Indolicidin-derivatives have potential as novel dual-action antimicrobial agents for treating resistant skin infections and warrant further preclinical investigations.
- 5 September 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0331796
Open AccessIndolicidin derivatives as potent dual-action antifungal and antibacterial agents for the treatment of skin infections: A comprehensive study from in vitro to in vivo evaluation
As listed by the WHO, the emergence of antibiotic-resistant pathogens, particularly Staphylococcus aureus and Pseudomonas aeruginosa, highlights the urgent need for novel antimicrobial agents. In parallel, fungal infections, especially those caused by Candida albicans, have also become increasingly prevalent and clinically challenging, further emphasizing the necessity for broad-spectrum therapeutic strategies. In particular, skin and soft tissue infections (SSTIs) caused by these bacteria and fungal are common in humans and can lead to severe complications if left untreated. Antimicrobial peptides (AMPs) have gained significant attention due to their broad-spectrum antimicrobial activity and immunomodulatory effects. Indolicidin, a naturally occurring cationic AMP, has demonstrated potent antibacterial and antifungal properties. In this study, we designed and synthesized a novel Indolicidin-derivative peptide IND-4,11K to enhance their antimicrobial activity and stability. The peptide was evaluated in vitro for their antimicrobial efficacy against Gram-positive, Gram-negative bacteria and Candida albicans. IND-4,11K was then prepared in 0–2% cream formula for in vivo testing in rabbit models. These findings suggest that modified Indolicidin-derivatives have potential as novel dual-action antimicrobial agents for treating resistant skin infections and warrant further preclinical investigations.
- 13 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (18) , e202500477
Harnessing Chemical Diversity to Disarm Bacterial Communication for 25 Years: Natural Products, Repurposed Drugs, Peptides, and Synthetic Quorum Sensing Inhibitors
Quorum sensing, a bacterial communication pathway, has emerged as a promising target for the development of alternative antimicrobial agents in the battle against bacterial resistance. In addition to biological investigations of quorum sensing mechanisms, substantial efforts have been made towards the rational design, synthesis, identification of natural products, and screening of commercial drugs towards this target. There are several individual reviews on the discovery of quorum sensing inhibitors; however, there has yet to be a comprehensive, detailed, and critical review providing a complete overview of the development of novel quorum sensing inhibitors, ranging from natural compounds, peptides, and repurposed drugs to synthetic molecules. This review provides a comprehensive and critical overview of quorum sensing inhibitors, highlighting key advances in their discovery, structure–activity relationships, and mechanisms of action over the past 25 years (2000–2025). It emphasizes several FDA‐approved drugs (e.g., azithromycin, ciprofloxacin, and paracetamol), natural compounds (e.g., ajoene, curcumin, quercetin, and carvacrol), peptides, and synthetic libraries that exhibit potent anti‐QS and antibiofilm activities against pathogenic bacteria. Furthermore, a systematic structural comparison and potential strategies for developing next‐generation therapeutics based on current advancements will be discussed.
- 13 August 2025
- Published by Wiley in ChemMedChem
- Vol. 20 (18) , e202500477
Harnessing Chemical Diversity to Disarm Bacterial Communication for 25 Years: Natural Products, Repurposed Drugs, Peptides, and Synthetic Quorum Sensing Inhibitors
Quorum sensing, a bacterial communication pathway, has emerged as a promising target for the development of alternative antimicrobial agents in the battle against bacterial resistance. In addition to biological investigations of quorum sensing mechanisms, substantial efforts have been made towards the rational design, synthesis, identification of natural products, and screening of commercial drugs towards this target. There are several individual reviews on the discovery of quorum sensing inhibitors; however, there has yet to be a comprehensive, detailed, and critical review providing a complete overview of the development of novel quorum sensing inhibitors, ranging from natural compounds, peptides, and repurposed drugs to synthetic molecules. This review provides a comprehensive and critical overview of quorum sensing inhibitors, highlighting key advances in their discovery, structure–activity relationships, and mechanisms of action over the past 25 years (2000–2025). It emphasizes several FDA‐approved drugs (e.g., azithromycin, ciprofloxacin, and paracetamol), natural compounds (e.g., ajoene, curcumin, quercetin, and carvacrol), peptides, and synthetic libraries that exhibit potent anti‐QS and antibiofilm activities against pathogenic bacteria. Furthermore, a systematic structural comparison and potential strategies for developing next‐generation therapeutics based on current advancements will be discussed.
- Open Access
- 21 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (32) , 26201-26215
Novel quinazoline-triazole-based N -hydroxybenzamides/ N -hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies
Two novel series of N -hydroxybenzamides and N -hydroxypropenamides bearing 4-oxoquinazoline and 1,2,3-triazole scaffolds were designed, synthesized, and evaluated for HDAC inhibition and anticancer activity.
- 21 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (32) , 26201-26215
Open AccessNovel quinazoline-triazole-based N -hydroxybenzamides/ N -hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies
Two novel series of N -hydroxybenzamides and N -hydroxypropenamides bearing 4-oxoquinazoline and 1,2,3-triazole scaffolds were designed, synthesized, and evaluated for HDAC inhibition and anticancer activity.
- 21 October 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (45) , 19144-19166
Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study
Histone deacetylases (HDACs) represent a particularly intriguing focus in the discovery and advancement of anticancer drugs. In this study, we detail the design, synthesis, and evaluation of novel hydroxamic acids featuring a 1H-benzo[d]imidazole component as potent inhibitors of HDACs and potential anticancer agents. A total of 54 novel compounds were designed and synthesized. Biological assessment revealed that compounds 29c, 31c, and 33c were the most effective inhibitors of HDACs and demonstrated significant potential as anti-cancer agents. Furthermore, compound 31c exhibited a 3-fold higher inhibitory activity against the mixture of HDAC isoforms in HeLa cell nuclear extract compared to the reference compound SAHA. Finally, docking studies on HDAC2 and HDAC6 revealed hydrogen bonds and pi-stacking interactions between hydrophobic and hydrophilic residues on the binding pocket surface, particularly with benzimidazole rings and anilide substituents, which enhance the inhibitory potency of the studied compounds.
- 21 October 2024
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 48 (45) , 19144-19166
Design, synthesis and bioevaluation of novel N-heterocyclic hydroxamic acids as histone deacetylase inhibitors and their antitumor activity study
Histone deacetylases (HDACs) represent a particularly intriguing focus in the discovery and advancement of anticancer drugs. In this study, we detail the design, synthesis, and evaluation of novel hydroxamic acids featuring a 1H-benzo[d]imidazole component as potent inhibitors of HDACs and potential anticancer agents. A total of 54 novel compounds were designed and synthesized. Biological assessment revealed that compounds 29c, 31c, and 33c were the most effective inhibitors of HDACs and demonstrated significant potential as anti-cancer agents. Furthermore, compound 31c exhibited a 3-fold higher inhibitory activity against the mixture of HDAC isoforms in HeLa cell nuclear extract compared to the reference compound SAHA. Finally, docking studies on HDAC2 and HDAC6 revealed hydrogen bonds and pi-stacking interactions between hydrophobic and hydrophilic residues on the binding pocket surface, particularly with benzimidazole rings and anilide substituents, which enhance the inhibitory potency of the studied compounds.